ArticleScientific reports2023
Treatment of 95 post-Covid patients with SSRIs.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Preparing for future pandemics: enhancing serotonin activation and interpersonal warmth through music therapy to aid in adolescent depression recovery post-COVID-19: a randomized controlled trial.BMC complementary medicine and therapies · 2026Trial
- Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.International journal of molecular sciences · 2026Review
- The role of peripheral serotonin in SARS-CoV-2 infectivity, COVID-19 treatment and long COVID.Immunology and cell biology · 2026Review
- Associations of selective serotonin reuptake inhibitors and long COVID risk in patients with depression: a retrospective cohort study.Infection · 2026Article
- Objectifying persistent subjective cognitive impairment following COVID-19 infection: cross-sectional data from an outpatient memory-clinic in Germany.European archives of psychiatry and clinical neuroscience · 2026Article
- Long-Term Health Consequences of SARS-CoV-2: Reaction Time and Brain Fog.Neurology international · 2025Article
- Perinatal citalopram exposure alters the gut composition and microbial metabolic profiles of Sprague-Dawley rat dams and female offspring but not male offspring.Biology of sex differences · 2025Article
- Neurobiological similarities and clinical differences between Post-COVID and depression; response to Bonnet and Kuhn 2024.European archives of psychiatry and clinical neuroscience · 2025Article
- Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.Life (Basel, Switzerland) · 2025Review
- Treatments for Long COVID autonomic dysfunction: a scoping review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Article
- Disruptions in serotonin- and kynurenine pathway metabolism in post-COVID: biomarkers and treatment.Frontiers in neurology · 2025Article
- Article
- The Intestine in Acute and Long COVID: Pathophysiological Insights and Key Lessons.The Yale journal of biology and medicine · 2024Review
- Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19.Computational and structural biotechnology journal · 2024Article
- [Post-COVID-19 condition-Clinical phenotyping in practice].Der Nervenarzt · 2024Article
- Is There such a Thing as Post-Viral Depression?: Implications for Precision Medicine.Biomolecules & therapeutics · 2024Review
- Association between selective serotonin reuptake inhibitors and mortality following COVID-19 among patients with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.Journal of medical case reports · 2024Article
- SSRI use during acute COVID-19 and risk of long COVID among patients with depression.BMC medicine · 2024Observational
- Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome.BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After Covid-19 infection, 12.5% develops post-Covid-syndrome (PCS). Symptoms indicate numerous affected organ systems. After a year, chronic fatigue, dysautonomia and neurological and neuropsychiatric complaints predominate. In this study, 95 PCS patients were treated with selective serotonin reuptake inhibitors (SSRIs). This study used an exploratory questionnaire and found that two-thirds of patients had a reasonably good to strong response on SSRIs, over a quarter of patients had moderate response, while 10% reported no response. Overall, patients experienced substantial improved well-being. Brainfog and sensory overload decreased most, followed by chronic fatigue and dysautonomia. Outcomes were measured with three different measures that correlated strongly with each other. The response to SSRIs in PCS conditions was explained by seven possible neurobiological mechanisms based on recent literature on PCS integrated with already existing knowledge. Important for understanding these mechanisms is the underlying biochemical interaction between various neurotransmitter systems and parts of the immune system, and their dysregulation in PCS. The main link appears to be with the metabolic kynurenine pathway (KP) which interacts extensively with the immune system. The KP uses the same precursor as serotonin: tryptophan. The KP is overactive in PCS which maintains inflammation and which causes a lack of tryptophan. Finally, potential avenues for future research to advance this line of clinical research are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.